Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 18
2002 47
2003 89
2004 83
2005 106
2006 124
2007 170
2008 223
2009 292
2010 269
2011 290
2012 311
2013 286
2014 316
2015 339
2016 327
2017 306
2018 327
2019 281
2020 317
2021 303
2022 18
Text availability
Article attribute
Article type
Publication date

Search Results

4,247 results
Results by year
Filters applied: . Clear all
Page 1
Rosuvastatin/Ezetimibe: A Review in Hypercholesterolemia.
Lamb YN. Lamb YN. Am J Cardiovasc Drugs. 2020 Aug;20(4):381-392. doi: 10.1007/s40256-020-00421-1. Am J Cardiovasc Drugs. 2020. PMID: 32648167 Review.
In well-designed clinical trials evaluating the therapeutic efficacy of rosuvastatin/ezetimibe administered as either separate agents or as an FDC, rosuvastatin/ezetimibe was significantly more effective than rosuvastatin monotherapy (including at double the …
In well-designed clinical trials evaluating the therapeutic efficacy of rosuvastatin/ezetimibe administered as either separate agents …
Rosuvastatin: Beyond the cholesterol-lowering effect.
Cortese F, Gesualdo M, Cortese A, Carbonara S, Devito F, Zito A, Ricci G, Scicchitano P, Ciccone MM. Cortese F, et al. Pharmacol Res. 2016 May;107:1-18. doi: 10.1016/j.phrs.2016.02.012. Epub 2016 Mar 2. Pharmacol Res. 2016. PMID: 26930419 Review.
Rosuvastatin is a fully synthetic statin wich acts by interfering with the endogenous synthesis of cholesterol through competitively inhibiting the 3-hydroxy-3-methylglutaryl coenzyme A reductase, a liver enzyme responsible of the rate-limiting step in cholesterol synthesi …
Rosuvastatin is a fully synthetic statin wich acts by interfering with the endogenous synthesis of cholesterol through competitively …
Counting on natural products for drug design.
Rodrigues T, Reker D, Schneider P, Schneider G. Rodrigues T, et al. Nat Chem. 2016 Jun;8(6):531-41. doi: 10.1038/nchem.2479. Epub 2016 Apr 25. Nat Chem. 2016. PMID: 27219696 Review.
An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia.
Strilchuk L, Tocci G, Fogacci F, Cicero AFG. Strilchuk L, et al. Expert Opin Pharmacother. 2020 Apr;21(5):531-539. doi: 10.1080/14656566.2020.1714028. Epub 2020 Feb 8. Expert Opin Pharmacother. 2020. PMID: 32036729 Review.
Patients with diabetes receive additional benefits from ezetimibe as they seem to absorb cholesterol more effectively than non-diabetic ones, because of increased NPC1L1 gene expression. Ezetimibe augments rosuvastatin triglyceride-lowering and anti-inflammatory effects, a …
Patients with diabetes receive additional benefits from ezetimibe as they seem to absorb cholesterol more effectively than non-diabetic ones …
Rosuvastatin: Role in Secondary Prevention of Cardiovascular Disease.
Wander GS, Hukkeri MYK, Yalagudri S, Mahajan B, Panda AT. Wander GS, et al. J Assoc Physicians India. 2018 Mar;66(3):70-4. J Assoc Physicians India. 2018. PMID: 30341873 Review.
Data related to secondary prevention is limited with rosuvastatin. Most of the clinical evidences with rosuvastatin have shown more effective LDL reduction than other statins. More number of patients achieve LDL goals and reduction in intima thickness. This article …
Data related to secondary prevention is limited with rosuvastatin. Most of the clinical evidences with rosuvastatin have shown …
Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia.
Jin X, Kim MH, Han KH, Hong SJ, Ahn JC, Sung JH, Cho JM, Lee HC, Choi SY, Lee K, Kim WS, Rhee MY, Kim JH, Hong SP, Yoo BS, Cho EJ, Lee JH, Kim PJ, Park CG, Hyon MS, Shin JH, Lee SH, Sung KC, Hwang J, Kwon K, Chae IH, Seo JS, Kim H, Lee H, Cho Y, Kim HS. Jin X, et al. J Clin Hypertens (Greenwich). 2020 Oct;22(10):1835-1845. doi: 10.1111/jch.13893. Epub 2020 Sep 16. J Clin Hypertens (Greenwich). 2020. PMID: 32937023 Free PMC article. Clinical Trial.
We enrolled 202 patients who were randomly divided into the following three groups: telmisartan/amlodipine 80/5 mg + rosuvastatin 20 mg, telmisartan 80 mg + rosuvastatin 20 mg, and telmisartan/amlodipine 80/5 mg. ...The Least-Square (LS) mean (SE) for changes in MSS …
We enrolled 202 patients who were randomly divided into the following three groups: telmisartan/amlodipine 80/5 mg + rosuvastatin 20 …
Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients' Pharmacogenetic Profile.
Vrkić Kirhmajer M, Macolić Šarinić V, Šimičević L, Ladić I, Putarek K, Banfić L, Božina N. Vrkić Kirhmajer M, et al. Basic Clin Pharmacol Toxicol. 2018 Oct;123(4):509-518. doi: 10.1111/bcpt.13035. Epub 2018 Jun 29. Basic Clin Pharmacol Toxicol. 2018. PMID: 29734517 Free article. Review.
There are several possible factors which could contribute to the onset of rhabdomyolysis: old age, initially excessive rosuvastatin dose, drug-drug interactions (DDI) on metabolic enzymes (CYPs and UGTs) and drug transporter levels (ABCB1, ABCG2, OATP1B1) and pharmacogenet …
There are several possible factors which could contribute to the onset of rhabdomyolysis: old age, initially excessive rosuvastatin d …
Efficacy and safety of rosuvastatin vs. atorvastatin in lowering LDL cholesterol : A meta-analysis of trials with East Asian populations.
Zhang L, Zhang S, Yu Y, Jiang H, Ge J. Zhang L, et al. Herz. 2020 Sep;45(6):594-602. doi: 10.1007/s00059-018-4767-2. Epub 2018 Nov 27. Herz. 2020. PMID: 30483816 English.
Both rosuvastatin and atorvastatin were well tolerated, with similar incidences of adverse events. CONCLUSION: Similar to the VOYAGER meta-analysis, which reported a greater efficacy of rosuvastatin in comparison with atorvastatin and simvastatin in Caucasian patien …
Both rosuvastatin and atorvastatin were well tolerated, with similar incidences of adverse events. CONCLUSION: Similar to the VOYAGER …
Rosuvastatin protects against coronary microembolization-induced cardiac injury via inhibiting NLRP3 inflammasome activation.
Chen A, Chen Z, Zhou Y, Wu Y, Xia Y, Lu D, Fan M, Li S, Chen J, Sun A, Zou Y, Qian J, Ge J. Chen A, et al. Cell Death Dis. 2021 Jan 12;12(1):78. doi: 10.1038/s41419-021-03389-1. Cell Death Dis. 2021. PMID: 33436548 Free PMC article.
In vivo study, mice with CME were treated with 40 mg/kg/d rosuvastatin (RVS) orally or a selective NLRP3 inflammasome inhibitor MCC950 intraperitoneally (20 mg/kg/d). ...
In vivo study, mice with CME were treated with 40 mg/kg/d rosuvastatin (RVS) orally or a selective NLRP3 inflammasome inhibitor MCC95 …
Perioperative Rosuvastatin in Cardiac Surgery.
Zheng Z, Jayaram R, Jiang L, Emberson J, Zhao Y, Li Q, Du J, Guarguagli S, Hill M, Chen Z, Collins R, Casadei B. Zheng Z, et al. N Engl J Med. 2016 May 5;374(18):1744-53. doi: 10.1056/NEJMoa1507750. N Engl J Med. 2016. PMID: 27144849 Free article. Clinical Trial.
RESULTS: The concentrations of low-density lipoprotein cholesterol and C-reactive protein after surgery were lower in patients assigned to rosuvastatin than in those assigned to placebo (P<0.001). However, the rate of postoperative atrial fibrillation did not differ sig …
RESULTS: The concentrations of low-density lipoprotein cholesterol and C-reactive protein after surgery were lower in patients assigned to …
4,247 results